FXR an emerging therapeutic target for the treatment of atherosclerosis
Atherosclerosis is the leading cause of illness and death. Therapeutic strategies aimed at reducing cholesterol plasma levels have shown efficacy in either reducing progression of atherosclerotic plaques and atherosclerosis-related mortality. The farnesoid-X-receptor (FXR) is a member of metabolic n...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837604/ |